Foundation Medicine to Share 10 Abstracts at AACR23 Demonstrating the Unique Capabilities of Its Molecular Profiling Tests to Advance Precision Cancer Care
New studies demonstrate the utility of Foundation Medicine’s robust data and novel methylation sequencing to provide doctors and researchers with high-quality solutions for treatment decision making and therapy development
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present a total of 10 studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida.
Presentation highlights:
- Over the past several years, there has been great progress in the ability to identify shed pieces of tumor, called circulating tumor DNA (ctDNA), within a cancer patient’s blood. In partnership with South Australian Immunogenomics Cancer Institute, Saint Bartholomew’s Hospital and Genentech, Foundation Medicine researchers used its novel methylation sequencing research platform to detect ctDNA as a prognostic biomarker in overall survival for patients with metastatic castrate resistant prostate cancer (mCRPC). Results from ctDNA evaluation as early as 6 weeks post treatment initiation were comparable to prostate specific antigen (PSA) response in second line mCRPC, providing an early non-invasive readout that is independent of PSA for monitoring therapy response in late stage mCRPC.
- Historical barriers in the study of small cell lung cancer (SCLC) include the relative lack of human tumors studied, limited real-world data, and the lack of access to longitudinal samples to understand tumor evolution. In partnership with Stanford University and Vanderbilt University Medical Center, Foundation Medicine researchers conducted what is believed to be the largest SCLC study known to date to provide an improved understanding of genetic subtypes in SCLC, including patient ancestry and biopsy site-specific patterns, and better inform mechanisms of transformation to SCLC from non-small cell lung cancer that may further guide the development of personalized therapies for subsets of patients with this fatal tumor.
“Our experience sequencing over one million patient samples has allowed us to continuously improve our approach and have high confidence in the genomic abnormalities we detect and the results we deliver,” said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. “We are committed to bringing high-quality, differentiated and sustainable solutions, like options for sensitive ctDNA monitoring, to our physician and researcher partners so that they can provide all patients with the best treatment options for their unique cancers.”
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR, please visit AACR.org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR23 and visit us in person at Booth #3053.
| Abstract # | Title | Collaborator | Product |
| Posters |
| ||
| 305 Sunday, April 16 1:30 – 5:00 PM
| POLE variant detection and classification is critical for identifying patients who may benefit from immunotherapy |
| FoundationOne®CDx and FoundationOne®Liquid CDx |
| 228 Sunday, April 16 1:30 – 5:00 PM
| Recurrent mitochondrial mutations in thyroid cancer |
| FoundationOne®CDx |
| 931 Sunday, April 16 1:30 – 5:00 PM
| Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation | Stanford University & Vanderbilt University Medical Center | FoundationOne®CDx, Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database |
| 933 Sunday, April 16 1:30 – 5:00 PM
| The landscape of treatment patterns in non-small cell lung cancer post EGFR TKI treatment described by real world data from 428 patients | Flatiron Health, One Oncology | Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database |
| 938 Sunday, April 16 1:30 – 5:00 PM
| Outcomes of Molecular Tumor Board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia | King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center | FoundationOne®CDx |
| 966 Sunday, April 16 1:30 – 5:00 PM
| Exploration of a novel HRD signature (HRDsig) as a biomarker for rucaparib benefit in ARIEL2 | Clovis Oncology, Imperial College London | FoundationOne®CDx |
| 305 Monday, April 17 9:00 a.m. – 12:30 p.m.
| Co-occurrence of alterations impacting telomere elongation |
| FoundationOne®CDx |
| 2289 Monday, April 17 9:00 a.m. – 12:30 p.m.
| Predicting tumor somatic vs versus clonal hematopoiesis (CH) origin for short variants (SV) with FoundationOne®Liquid CDx assay |
| FoundationOne®Liquid CDx |
| 3362 Monday, April 17 1:30 – 5:00 p.m.
| Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay | South Australian Immunogenomics Cancer Institute, Genentech, St. Bartholomew’s Hospital | Research methylation assay |
| 3395 Monday, April 17 1:30 – 5:00 p.m.
| Clinical Impact of FGFR inhibitors on FGFR2 Fusion Positive Pancreatic Cancer | Ohio State University | FoundationOne®CDx |
About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Source: Foundation Medicine
Contacts
Abigail Linehan, 781-534-3210
[email protected]
